Opendata, web and dolomites

MAGELIA SIGNED

A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAGELIA project word cloud

Explore the words cloud of the MAGELIA project. It provides you a very rough idea of what is the project "MAGELIA" about.

sme    clinicians    medium    preparation    round    larger    inorevia    tool    generation    2021    sequencing    curie    finish    expensive    confirmed    biotech    entirely    revolution    2016    automated    backed    initiate    renowned    billion    awards    business    patents    breaking    company    scientists    ignite    put    seed    platform    institut    modern    samples    spin    miniaturized    microfluidics    won    15    struggle    paris    france    throughput    accelerate    earlier    persons    first    raw    medicine    reagents    genomics    upstream    faster    prototype    trl6    leverages    advisory    labs    inception    platforms    companies    ready    ten    instrument    rights    times    leader    secured    400    volumes    miniaturised    board    biological    team    meet    preparations    succeed    democratise    series    reproducibility    turnover    1000    cnrs    smaller    library    grants    trl8    commercialization    ngs    market    manual    holds    biologists    off    biology    fast    cheaper    scarce    exclusive    ground    customers    talents    engineers    accelerating    tackle    magelia    pharmacy   

Project "MAGELIA" data sheet

The following table provides information about the project.

Coordinator
INOREVIA 

Organization address
address: 6 RUE JEAN CALVIN
city: PARIS
postcode: 75005
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙000 €
 EC max contribution 1˙955˙100 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INOREVIA FR (PARIS) coordinator 1˙955˙100.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform. After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market. To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round. The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGELIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGELIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More  

B2BMarketplace (2019)

The first B2B marketplace for Fast Moving Consumer Goods, connecting all brand manufacturers and retailers globally

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More